Non-alcoholic fatty liver disease

The Lancet, Journal Year: 2021, Volume and Issue: 397(10290), P. 2212 - 2224

Published: April 21, 2021

Language: Английский

---

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2020, Volume and Issue: 18(4), P. 223 - 238

Published: Dec. 21, 2020

Language: Английский

---

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease

Gastroenterology, Journal Year: 2019, Volume and Issue: 156(5), P. 1264 - 1281.e4

Published: Jan. 18, 2019

Language: Английский

---

Advancing the global public health agenda for NAFLD: a consensus statement

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2021, Volume and Issue: 19(1), P. 60 - 78

Published: Oct. 27, 2021

Language: Английский

---

Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States

Clinical Gastroenterology and Hepatology, Journal Year: 2020, Volume and Issue: 19(3), P. 580 - 589.e5

Published: June 9, 2020

Language: Английский

---

Changing epidemiology, global trends and implications for outcomes of NAFLD

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(3), P. 842 - 852

Published: May 10, 2023

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common globally, currently estimated to affect 38% of global population. A minority patients with NAFLD will progress cirrhosis or hepatocellular carcinoma, but total number this vast population that risk such severe outcomes is increasing. Worryingly, persons are affected by at an earlier age, suggesting they have longer time develop complications. With considerable changes in diet composition and urbanization, obesity type 2 diabetes among population, particular developing countries, proportion projected be further Yet, there large geographical discrepancies prevalence rates its inflammatory component non-alcoholic steatohepatitis (NASH). Such differences partly related differing socio-economic milieus, also genetic predisposition.This narrative review discusses recent epidemiology NASH from regional perspectives, as well special populations. We discuss consequences these can on hepatic extra-hepatic events.

Language: Английский

---

What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’

Liver International, Journal Year: 2020, Volume and Issue: 40(6), P. 1254 - 1261

Published: April 17, 2020

Abstract In medicine, language matters and the words used to name describe a disease can have profound impact on patients their families. Over last two decades, many criticisms been voiced about nomenclature definition of non‐alcoholic fatty liver (NAFLD) in regards not only prominent role that alcohol plays but also negative impacts including trivialization, stigmatization less consideration health policy. Recently, consensus international experts proposed acronym be changed from NAFLD metabolic (dysfunction) associated or ‘MAFLD’. This change goes far beyond mere semantic revision may first step catalyses process better conceptualize for promotion, patient orientation, case identification, ongoing clinical trials services delivery. Here we review history of, definitions MAFLD context advancing our understanding pathogenesis disease. We address reasons, signals, promises, challenges way going forward various stakeholder perspectives.

Language: Английский

---

Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts

BMC Medicine, Journal Year: 2019, Volume and Issue: 17(1)

Published: May 20, 2019

Non-alcoholic fatty liver disease (NAFLD) is a common condition that progresses in some patients to steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). Here we used healthcare records of 18 million adults estimate risk acquiring advanced diagnoses with NAFLD or NASH compared individually matched controls. Data were extracted from four European primary care databases representing the UK, Netherlands, Italy Spain. Patients recorded diagnosis (NAFLD/NASH) followed up for incident HCC diagnoses. Each coded NAFLD/NASH patient was 100 "non-NAFLD" by practice site, gender, age ± 5 years visit within 6 months. Hazard ratios (HR) estimated using Cox models adjusted smoking status pooled across random effects meta-analyses. Out 18,782,281 adults, identified 136,703 NAFLD/NASH. Coded more likely have diabetes, hypertension obesity than HR controls 4.73 (95% CI 2.43–9.19) HCC, 3.51 1.72–7.16). either outcome higher those high-risk Fib-4 scores. The strongest independent predictor baseline diabetes. Real-world population data show increases life-threatening outcomes. Diabetes an diagnosis, emphasising need identify specific groups at highest risk.

Language: Английский

---

Dietary Fructose and the Metabolic Syndrome

Nutrients, Journal Year: 2019, Volume and Issue: 11(9), P. 1987 - 1987

Published: Aug. 22, 2019

Abstract: Consumption of fructose, the sweetest all naturally occurring carbohydrates, has increased dramatically in last 40 years and is today commonly used commercially soft drinks, juice, baked goods. These products comprise a large proportion modern diet, particular children, adolescents, young adults. A body evidence associate consumption fructose other sugar-sweetened beverages with insulin resistance, intrahepatic lipid accumulation, hypertriglyceridemia. In long term, these risk factors may contribute to development type 2 diabetes cardiovascular diseases. Fructose absorbed small intestine metabolized liver where it stimulates fructolysis, glycolysis, lipogenesis, glucose production. This result hypertriglyceridemia fatty liver. Therefore, understanding mechanisms underlying intestinal hepatic metabolism important. Here we review recent linking excessive health markers components Metabolic Syndrome.

Language: Английский

---

MAFLD: How is it different from NAFLD?

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S17 - S31

Published: Nov. 29, 2022

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer related systemic metabolic dysregulation. The name change from nonalcoholic (NAFLD) MAFLD comes with a simple set of criteria enable easy diagnosis at bedside for general medical community, including primary care physicians. Since introduction term, there have been key areas which superiority over traditional NAFLD terminology has demonstrated, risk and extrahepatic mortality, associations, identifying high-risk individuals. Additionally, adopted by number leading pan-national national societies due its concise diagnostic criterion, removal requirement exclude concomitant diseases, reduction stigma associated this condition. current article explores differences between diagnosis, benefit, some potential limitations, how opened up new fields research.

Language: Английский

---